Financiere des Professionnels Fonds d investissement inc. Invests $1.08 Million in Vaxcyte, Inc. $PCVX

Financiere des Professionnels Fonds d investissement inc. purchased a new stake in Vaxcyte, Inc. (NASDAQ:PCVX) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 18,600 shares of the company’s stock, valued at approximately $1,081,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in PCVX. JPMorgan Chase & Co. grew its holdings in Vaxcyte by 30.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,565,036 shares of the company’s stock valued at $56,373,000 after buying an additional 366,266 shares in the last quarter. NEXTBio Capital Management LP purchased a new position in shares of Vaxcyte during the 4th quarter worth $4,406,000. Norges Bank acquired a new position in shares of Vaxcyte during the 4th quarter valued at about $56,703,000. Universal Beteiligungs und Servicegesellschaft mbH boosted its position in shares of Vaxcyte by 105.3% during the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 70,124 shares of the company’s stock valued at $3,236,000 after acquiring an additional 35,974 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its holdings in shares of Vaxcyte by 147.7% in the fourth quarter. Assenagon Asset Management S.A. now owns 544,728 shares of the company’s stock valued at $25,134,000 after purchasing an additional 324,778 shares during the period. Institutional investors and hedge funds own 96.78% of the company’s stock.

Vaxcyte Trading Up 0.3%

NASDAQ PCVX opened at $56.20 on Friday. The stock has a fifty day simple moving average of $52.34 and a 200-day simple moving average of $54.23. The stock has a market cap of $8.12 billion, a PE ratio of -8.17 and a beta of 1.22. Vaxcyte, Inc. has a twelve month low of $29.08 and a twelve month high of $65.00.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($2.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.74) by ($0.56). During the same quarter in the previous year, the firm posted ($1.04) EPS. Research analysts predict that Vaxcyte, Inc. will post -7.91 EPS for the current year.

Insider Buying and Selling at Vaxcyte

In other news, CEO Grant Pickering sold 2,000 shares of the company’s stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $55.23, for a total value of $110,460.00. Following the transaction, the chief executive officer directly owned 134,215 shares in the company, valued at approximately $7,412,694.45. This represents a 1.47% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew Guggenhime sold 10,000 shares of the stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $57.28, for a total transaction of $572,800.00. Following the transaction, the chief financial officer directly owned 104,395 shares of the company’s stock, valued at $5,979,745.60. The trade was a 8.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 75,448 shares of company stock worth $4,091,197 over the last three months. Insiders own 3.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on PCVX shares. Wall Street Zen cut shares of Vaxcyte from a “sell” rating to a “strong sell” rating in a research report on Tuesday, April 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a report on Monday, July 6th. Finally, Zacks Research cut shares of Vaxcyte from a “hold” rating to a “strong sell” rating in a research note on Tuesday. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $86.00.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.